Pluri Inc. Common Stock (PLUR)

About PLUR

Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform. Its product candidates include PLX-PAD, that is composed of m…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

127

Website

pluri-biotech.com/

Fundamentals

1-day range

$1.46$1.64

Market cap

$16.99M

P/E (trailing)

—

P/E (forward)

-0.81

EPS (trailing)

$-2.89

Dividend yield

—

Beta

0.66

Avg. volume

29.1K

Dividend pay date

July 25, 2019

Pluri Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• PLUR

  Pluri Inc. Common Stock

  $1.53

  ▲ 0.00%
  Market cap $16.99MP/E —
  $1.45$5.68
• JSPR

  Jasper Therapeutics Inc. Common Stock

  $0.6782

  ▼ 2.98%
  Market cap $16.98MP/E —
  $0.3151$2.96
• PASG

  Passage Bio Inc. Common Stock

  $4.52

  ▲ 4.39%
  Market cap $14.40MP/E —
  $3.29$20
• SNTI

  Senti Biosciences Holdings Inc. Common Stock

  $0.377

  ▼ 0.26%
  Market cap $11.53MP/E —
  $0.3305$2.88
• INTS

  Intensity Therapeutics Inc. Common stock

  $4.25

  ▲ 0.95%
  Market cap $11.51MP/E —
  $3.51$43.5
• CRIS

  Curis Inc. Common Stock

  $1.49

  ▲ 2.76%
  Market cap $10.04MP/E —
  $1.4$39
• BCDA

  BioCardia Inc. Common Stock

  $1.16

  ▼ 0.85%
  Market cap $9.45MP/E —
  $0.75$2.29

P/E shows — for peers not currently carrying a live signal of their own.

Institutional Ownership

March 31, 2026

Total shares held

26.9K

Total value held

$90.9K

Institutional holders

13